Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA
· Real-Time Price · USD
1.26
0.01 (0.40%)
At close: Sep 08, 2025, 3:59 PM
1.24
-1.60%
After-hours: Sep 08, 2025, 06:23 PM EDT
Company Description
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease.
The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
It has a license agreement with Factor Bioscience Limited.
The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025.
Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Ernexa Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 29, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Sanjeev Luther |
Contact Details
Address: 10355 Science Center Drive Cambridge, Massachusetts United States | |
| Website | https://www.ernexatx.com |
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082308 |
| ISIN Number | US1140823089 |
| Employer ID | 31-1103425 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President & Director |
| Dorothy J. Clarke | General Counsel |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Jul 07, 2025 | 4 | Filing |
| Jul 07, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 424B3 | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 11, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | S-8 | Filing |
| Jun 11, 2025 | S-3 | Filing |